ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2 and NAV3 cancer screening test. It uses GeneICE technology, which enables silencing of specific genes by targeted histone deacetylation for chromatin condensation. ValiRx’s ValiMedix division sells and distributes oncology therapeutics. The company’s ValiPharma division is a therapeutics division that provides technologies for the treatment of cancer. Its’s ValiFinn division offers research and development services. The company also develops clinical trials, which are used to treat hormone induced refractory prostate cancer and other conditions of hormone. ValiRx is headquartered in Nuneaton, the UK.
Headquarters
United Kingdom
Address
Eliot Park Innovation Centre, 4 Barling Way, Nuneaton, England, CV107RH
Website
www.valirx.com
Telephone
44 24 76796496
No of Employees
8
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VAL (LON)
EPS
XYZ
Net Income (2021)
XYZ
-55.9%
(2021 vs 2020)
Market Cap*
$5.5M
Net Profit Margin (0 vs)
XYZ
0.0%
(2021 vs 2020)
* As of and is in US$
ValiRx Plc premium industry data and analytics
Products and Services
| Products |
|---|
| VAL201 |
| VAL301 |
| VAL401 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with STINGRAY BIO to investigate a lead series of drug candidates for use in oncology. |
| 2023 | Contracts/Agreements | In August, Inaphaea BioLabs Limited entered into a services agreement with Agility Life Sciences Limited for formulation development and optimization, pre-formulation studies and analysis. |
| 2023 | Contracts/Agreements | In July, the company signed master services agreement and project statement of work with Inaphaea BioLabs to the work, with subsequent invoices anticipated at milestones during the project period. |
Competitor Comparison
| Key Parameters | ValiRx Plc | Myovant Sciences Ltd | Silence Therapeutics Plc | Scancell Holdings Plc | ReNeuron Group Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | Nuneaton | London | London | Oxford | Bridgend |
| State/Province | England | - | England | Oxfordshire | Wales |
| No. of Employees | 8 | 579 | 116 | 51 | 34 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Suzanne Dilly | Chief Executive Officer; Director | Executive Board | 2020 | 45 |
| Gerry Desler | Director; Secretary; Chief Financial Officer | Executive Board | 2006 | 78 |
| Cathy Tralau-Stewart | Chief Scientific Officer | Senior Management | 2022 | - |
| Kumar Nawani | Head - Operations | Senior Management | - | - |
| Kevin Cox | Chairman | Non Executive Board | 2020 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer